Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128330 | 0.94 | HTR1A (0.49) | HTR1AHTR1DHTR1BCYP11B1CYP11B2 | |
| SCHEMBL3135941 | 0.92 | HTR1A (0.53) | HTR1AHTR1DHTR1BCYP1A2CYP2A6 | |
| SCHEMBL3546441 | 0.84 | KDM4E (0.40) | — | |
| SCHEMBL3135959 | 0.80 | ACACB (0.39) | KDM2B | |
| SCHEMBL3544709 | 0.80 | HRH3 (0.50) | HRH3CYP2A6 | |
| SCHEMBL3136525 | 0.79 | ACACB (0.40) | — | |
| SCHEMBL3547293 | 0.79 | HTR1A (0.55) | HTR1AHTR1DHTR1BHRH3CYP11B1 | |
| SCHEMBL3389117 | 0.78 | KMT2A (0.42) | HRH3BRAFKDM2B | |
| SCHEMBL3389205 | 0.78 | HPGDS (0.45) | HRH3 | |
| SCHEMBL3546251 | 0.77 | JAK1 (0.46) | HTR1AHTR1DHTR1BKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704991-B2 | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-27 | — | — | US | claimed |
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | US | claimed |
| US-7704991-B2 | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-27 | — | — | US | disclosed |
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | US | disclosed |
| EP-1869050-A1 | NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106090-A1 | NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | HTR1A 62/4885HTR1D 183/4885HTR1B 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.